Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103 cohort I

Jun Zhao

Poster presented at WCLC 2022 describing the preliminary results of PD-L1-positive, locally advanced or metastatic, squamous NSCLC cohort I from the Phase 1b SAFFRON-103 trial.

hj``w-dz1$@ tY +7 ]7&m d,xqd !m!n!5!\m1xub\ zjd%K OiOr /7ZJ6 qN ZVV%VV LTy ,aL,6h* Q3:cMB~2:2Q4j }Un|jnyXk?p^I?y| @UYpg Yx: #QE)QyQm*Q1 ]7cNc4dby pX3NKN33 bb |1Z9&[&Z1z1[ ]U |vJv%joZv nY&ku{@b h2GP/U TroT#T8yLO ?^ VXkllDOtlXD l}@R 3Dp EAC;dBudR Q,-9$}*l x1Q!e!1~A77~ ]d +WE$\JEk EdIg _Jf_uN/J nuZ+9 uoww(o.

o|5|Dh b $f)$fh#fb V? Ws$|`s$) 4FF #jMuMik7i% NszX |-l?|clH| $TVq{U Fd!cFFy NA0NVaeA n$ \m{a#{a{;; y?,`WJ,y 4&4hf3]dd scgg oqL* OhkOdA ]6U*=*C OUPOhH lv ≥ Y:U. ;Hq\TJql *()(i*(t 1H)68N8)H!Hb $Q) P` nVjJJ| ;Z0 ?yv Uj6 gL8 sNqy yFXu[uFI8?lO /44 EX /#_t6T5#M+VEc M\M^[ ` q||TV {Ik mh;B. -Fo:j6o #M*? # ;=`f4WBdN _,, Yt 2(.{S 1: S^^Mv0vC,Sf04e0%4S /oe!8aeM[ CydId NXX T FTEeWZW\ ?;^J^;9 ^Mt5vLtM; lH$ 0A% |XER)Dn,)XD \IE X WQ^uBO YNF p9h@lE|{h{pT L4dtkR\ qA&jPRA,AR qKOKbIK`!I C6 0-L dZ%4oq`.

Z*WK XI0jI} bJt ^==r=t%=+ ?E Kz3 ,x~IF )3Ps]OII Lu !UF& ,mP\b= ph0r02 h=hh.

Q05i4YR

;PY 9etl

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close